ObsEva (CHIX:OBSNZ) Change In Receivables : CHF3.01 Mil (TTM As of Dec. 2022)

View and export this data going back to 2018. Start your Free Trial

What is ObsEva Change In Receivables?

ObsEva's change in receivables for the quarter that ended in Dec. 2022 was CHF-0.17 Mil. It means ObsEva's Accounts Receivable increased by CHF0.17 Mil from Sep. 2022 to Dec. 2022 .

ObsEva's change in receivables for the fiscal year that ended in Dec. 2022 was CHF2.99 Mil. It means ObsEva's Accounts Receivable declined by CHF2.99 Mil from Dec. 2021 to Dec. 2022 .

ObsEva's Accounts Receivable for the quarter that ended in Dec. 2022 was CHF0.24 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. ObsEva's Days Sales Outstanding for the three months ended in Dec. 2022 was 1.17.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. ObsEva's liquidation value for the three months ended in Dec. 2022 was CHF0.51 Mil.

ObsEva Change In Receivables Historical Data

The historical data trend for ObsEva's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ObsEva Change In Receivables Chart

ObsEva Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Receivables

Get a 7-Day Free Trial

-0.10

0.19

0.29

-2.43

2.99

ObsEva Quarterly Data
	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22
Change In Receivables	Get a 7-Day Free Trial															0.24	2.42	0.75	0.01	-0.17

ObsEva Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF3.01 Mil.

ObsEva (CHIX:OBSNz) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

ObsEva's Days Sales Outstanding for the quarter that ended in Dec. 2022 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.235	/	18.294	*	91
=	1.17

2. In Ben Graham's calculation of liquidation value, ObsEva's accounts receivable are only considered to be worth 75% of book value:

ObsEva's liquidation value for the quarter that ended in Dec. 2022 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	7.848	-	7.51	+	0.75 * 0.235	+	0.5 * 0
=	0.51

ObsEva Change In Receivables Related Terms

Thank you for viewing the detailed overview of ObsEva's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

ObsEva (CHIX:OBSNZ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ObsEva SA (CHIX:OBSNz) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Chemin des Aulx, 12, Plan-les-Ouates, Geneva, CHE, 1228

Website

https://www.obseva.com

ObsEva SA is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman's reproductive health and pregnancy. The Company operates in one segment, which is the research and development of innovative women's reproductive, health, and pregnancy therapeutics. It includes advancing a development program for Nolasiban, an oral oxytocin receptor agonist, focused on improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization (IVF). Geographically, the majority is from Switzerland.

ObsEva (CHIX:OBSNZ) Headlines

No Headlines